TRCT
BCTX

Tower Research Capital (TRC)’s Briacell Therapeutics BCTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9
Closed -$64 – 5134
2025
Q4 		$64 Buy
+9
New +$95 ﹤0.01% 5068
2025
Q2 		– Sell
-1
Closed -$37 – 5261
2025
Q1 		$37 Buy
+1
New +$48 ﹤0.01% 5087
2024
Q3 		– Sell
-4
Closed -$602 – 5706
2024
Q2 		$602 Sell
4
-1
-20% -$283 ﹤0.01% 5293
2024
Q1 		$2.25K Buy
5
+1
+25% +$551 ﹤0.01% 5088
2023
Q4 		$3.09K Hold
4
– – ﹤0.01% 5127
2023
Q3 		$3.3K Sell
4
-5
-56% -$4.89K ﹤0.01% 5022
2023
Q2 		$8.92K Sell
9
-19
-68% -$18.8K ﹤0.01% 4359
2023
Q1 		$31K Buy
28
+4
+17% +$4.15K ﹤0.01% 2946
2022
Q4 		$16K Buy
24
+9
+60% +$7.62K ﹤0.01% 3323
2022
Q3 		$13K Sell
15
-7
-32% -$7.02K ﹤0.01% 4254
2022
Q2 		$18K Sell
22
-1
-4% -$988 ﹤0.01% 3885
2022
Q1 		$35K Sell
23
-7
-23% -$8.28K ﹤0.01% 3000
2021
Q4 		$38K Buy
30
+4
+15% +$5.24K ﹤0.01% 2996
2021
Q3 		$31K Buy
26
+4
+18% +$3.68K ﹤0.01% 3345
2021
Q2 		$18K Buy
+22
New +$13.7K ﹤0.01% 3979

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Tower Research Capital (TRC)'s BCTX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Briacell Therapeutics (BCTX) in Q1 2026, closing a stake of 9 shares — an estimated $64 sold.

Tower Research Capital (TRC) first reported a position in BCTX in Q2 2021 and held it in 15 quarters. The position peaked at $38K in Q4 2021. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Briacell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9 Briacell Therapeutics shares in Q1 2026, an estimated $64.
  • Tower Research Capital (TRC) first reported a position in Briacell Therapeutics in Q2 2021 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s Briacell Therapeutics position peaked at $38K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.